ARB, ACEi, DRi Effects on COVID-19 Course Disease
BIRCOV
Effects of RAS Inhibitors (ARB, ACEi, DRI) in People With Hypertension 1-2 Stages on the Course of COVID-19 (BIRCOV Trial: ARB, ACEI, DRi Effects on COVID-19)
1 other identifier
observational
112
1 country
1
Brief Summary
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2020
CompletedFirst Submitted
Initial submission to the registry
April 23, 2020
CompletedFirst Posted
Study publicly available on registry
April 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 24, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2021
CompletedResults Posted
Study results publicly available
February 18, 2022
CompletedMarch 21, 2023
August 1, 2021
1.3 years
April 23, 2020
August 27, 2021
March 18, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Level of BP in mm Hg
BP in patients one week before COVID-19 infection and 2, 4, 12, 24 weeks follow-up after COVID-19 onset
estimated at 2, 4, 12, 24 weeks after the start of COVID-19; data for 24 weeks are reported
Secondary Outcomes (5)
Number of Patients With Fever Above 37.2 on COVID-19 Course
estimated at 2, 4, 12 weeks after the COVID-19 onset
Number of Patients With Cough in COVID-19 Course
on 2,4 and 12 week from COVID-19 onset
Number of Patients With Throat Pain in COVID-19 Course
estimated at 2, 4, 12 weeks after the COVID-19 onset
Number of Patients With Diarrhea Inf COVID-19 Course
estimated at 2, 4, 12 weeks after the COVID-19 onset
Number of Patients Who Need to Apply to Hospital in COVID-19 Course
estimated at 2, 4, 12 weeks after the COVID-19 onset
Study Arms (3)
ARB group
Hypertensive patients with COVID-19 who received ARBs
ACEi group
Hypertensive patients with COVID-19 who received ACEis
DRi group
Hypertensive patients with COVID-19 who received direct renin inhibitor (DRis)
Interventions
routine drug intake
routine drug intake
Eligibility Criteria
patients with proved COVID-19 and preliminary documented hypertension 1-2 stage on RASi at the onset and COVID-19 course during 3 weeks
You may qualify if:
- Hypertensive person, stage 1-2
You may not qualify if:
- Hypertensive subjects, stage 3, HF (NYHA) 3-4
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical Practice Prof D.Ivanov
Kiev, Please Select, 01014, Ukraine
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Prof Dmytro Ivanov
- Organization
- Medical Practice Prof D.Ivanov
Study Officials
- STUDY CHAIR
Iryna Zavalna, MD
Nephrology clinic
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 4 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 23, 2020
First Posted
April 28, 2020
Study Start
April 1, 2020
Primary Completion
July 24, 2021
Study Completion
August 1, 2021
Last Updated
March 21, 2023
Results First Posted
February 18, 2022
Record last verified: 2021-08